Clinical Trial Materials

Otsuka Pharmaceutical and Osaka University Enter Exclusive License Agreement

April 20, 2022

Otsuka Pharmaceutical and Osaka University have entered an exclusive license agreement on a new anti-tumor antibody.

Huma and AstraZeneca Partner to Accelerate Innovation for Digital-First Patient Care

March 25, 2022

Huma has acquired AstraZeneca’s digital health platform, and AstraZeneca has become a shareholder of Huma in a partnership to accelerate digital-first patient care.

Selecting and Optimizing the Right Manufacturing Partner

March 02, 2022

Optimizing the use of partners for clinical trials depends on selecting the right contractor.

Insights into Outsourced vs. In-house Clinical Trial Services

March 02, 2022

Capacity concerns and regulatory compliance considerations will drive the decision about outsourcing the manufacture of clinical trial materials.

Recipharm Acquires Portuguese CDMO, GenIbet, Boosting Biologics Offering

February 01, 2022

Recipharm will build up its biologics service offering with the acquisition of GenIbet.

Pfizer Opens Gene Therapy Clinical Manufacturing Facility

December 16, 2021

Pfizer invested $68.5 million in a facility in Durham, NC.

Lonza Invests in Drug Product Manufacturing Services in China

August 25, 2021

Lonza plans to establish drug product manufacturing capabilities at is site in Guangzhou, China, to produce clinical trial and commercial supply in the country.

Purisys Adds ISO Certifications

July 12, 2021

Purisys is now certified for ISO 17025 for testing and calibration laboratories and ISO 17034 for reference material producers

Selexis and KBI Biopharma Partner with Immatics to Advance T-Cell Bispecific Program

July 01, 2021

Selexis and KBI Biopharma will use integrated services to advance Immatics’ TCR bispecifics drug development program to the IND stage.

Sanofi and GSK Report Strong Immune Response with COVID-19 Vaccine Candidate

May 18, 2021

Sanofi and GlaxoSmithKline reported that their adjuvanted recombinant COVID-19 vaccine candidate demonstrated strong immune responses across all adult age groups in a Phase II trial.